Ensign Peak Advisors
SOPH icon

Ensign Peak Advisors’s SOPHiA GENETICS SOPH Stock Holding History

Ensign Peak Advisors’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.57M Sell
444,654
-300
-0.1% -$1.52K ﹤0.01% 689
2026
Q1 		$2.2M Buy
444,954
+262,540
+144% +$1.28M ﹤0.01% 694
2025
Q4 		$852K Sell
182,414
-12,768
-7% -$57.8K ﹤0.01% 848
2025
Q3 		$929K Sell
195,182
-54,762
-22% -$188K ﹤0.01% 1068
2025
Q2 		$775K Buy
+249,944
New +$745K ﹤0.01% 1391

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $5.12B AUM 19.08% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

Ensign Peak Advisors's SOPH Position: Q2 2026 in Review

Ensign Peak Advisors reduced its SOPHiA GENETICS (SOPH) stake by 0.07% in Q2 2026, selling an estimated $1.52K and leaving 444,654 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #689.

Ensign Peak Advisors first reported a position in SOPH in Q2 2025 and has held it in 5 quarters since. 72 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

  • Ensign Peak Advisors held 444,654 shares of SOPHiA GENETICS worth $2.57M as of Q2 2026.
  • Ensign Peak Advisors sold 300 SOPHiA GENETICS shares in Q2 2026, an estimated $1.52K.
  • SOPHiA GENETICS made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #689 holding.
  • Ensign Peak Advisors first reported a position in SOPHiA GENETICS in Q2 2025 and has held it in 5 quarters since.
  • 72 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.